TTM
$1.54B
YoY change
-24.6%
5Y CAGR
-16.4%
Peak year (2019)
$7.04B
Cumulative operating income
$61.44B
Operating Income history chart for Biogen (BIIB) from 1985 to 2025
Latest: $1.88B
Operating Income growth chart for Biogen (BIIB) from 1985 to 2025
Latest: -24.6%
Operating Income history table for Biogen (BIIB) from 1985 to 2025
| 2025 | $1.88B | -24.6% | −$612.80M | ||
| 2024 | $2.49B | +18.7% | +$393.00M | ||
| 2023 | $2.10B | -27.4% | −$791.80M | ||
| 2022 | $2.89B | +3.5% | +$97.70M | ||
| 2021 | $2.79B | -39.2% | −$1.80B | ||
| 2020 | $4.59B | -34.8% | −$2.45B | ||
| 2019 | $7.04B | +19.6% | +$1.15B | ||
| 2018 | $5.89B | +10.2% | +$542.80M | ||
| 2017 | $5.35B | +3.8% | +$194.10M | ||
| 2016 | $5.15B | +5.3% | +$260.70M | ||
| 2015 | $4.89B | +23.1% | +$918.60M | ||
| 2014 | $3.97B | +57.9% | +$1.46B | ||
| 2013 | $2.52B | +36.8% | +$677.02M | ||
| 2012 | $1.84B | +6.6% | +$113.79M | ||
| 2011 | $1.72B | +38.1% | +$475.80M | ||
| 2010 | $1.25B | -3.6% | −$46.54M | ||
| 2009 | $1.30B | +6.7% | +$81.82M | ||
| 2008 | $1.21B | +55.6% | +$433.84M | ||
| 2007 | $779.77M | +77.2% | +$339.75M | ||
| 2006 | $440.02M | +86.4% | +$203.98M | ||
| 2005 | $236.04M | +443.7% | +$192.62M | ||
| 2004 | $43.42M | -105.0% | +$913.09M | ||
| 2003 | −$869.67M | -506.6% | −$1.08B | ||
| 2002 | $213.88M | -40.6% | −$146.32M | ||
| 2001 | $360.20M | +9.7% | +$31.84M | ||
| 2000 | $328.36M | +3.8% | +$12.11M | ||
| 1999 | $316.25M | +65.9% | +$125.61M | ||
| 1998 | $190.64M | +28.0% | +$41.67M | ||
| 1997 | $148.97M | +264.9% | +$108.14M | ||
| 1996 | $40.83M | +448.4% | +$33.38M | ||
| 1995 | $7.45M | -490.4% | +$9.35M | ||
| 1994 | −$1.91M | -108.8% | −$23.61M | ||
| 1993 | $21.70M | -24.1% | −$6.90M | ||
| 1992 | $28.60M | -2300.0% | +$29.90M | ||
| 1991 | −$1.30M | -262.5% | −$2.10M | ||
| 1990 | $800.00K | -108.9% | +$9.80M | ||
| 1989 | −$9.00M | -24.4% | +$2.90M | ||
| 1988 | −$11.90M | -50.8% | +$12.30M | ||
| 1987 | −$24.20M | -16.8% | +$4.90M | ||
| 1986 | −$29.10M | -11.6% | +$3.80M | ||
| 1985 | −$32.90M | — | — |
- 2025$1.88B-24.6%
- 2024$2.49B+18.7%
- 2023$2.10B-27.4%
- 2022$2.89B+3.5%
- 2021$2.79B-39.2%
- 2020$4.59B-34.8%
- 2019$7.04B+19.6%
- 2018$5.89B+10.2%
- 2017$5.35B+3.8%
- 2016$5.15B+5.3%
- 2015$4.89B+23.1%
- 2014$3.97B+57.9%
- 2013$2.52B+36.8%
- 2012$1.84B+6.6%
- 2011$1.72B+38.1%
- 2010$1.25B-3.6%
- 2009$1.30B+6.7%
- 2008$1.21B+55.6%
- 2007$779.77M+77.2%
- 2006$440.02M+86.4%
- 2005$236.04M+443.7%
- 2004$43.42M-105.0%
- 2003−$869.67M-506.6%
- 2002$213.88M-40.6%
- 2001$360.20M+9.7%
- 2000$328.36M+3.8%
- 1999$316.25M+65.9%
- 1998$190.64M+28.0%
- 1997$148.97M+264.9%
- 1996$40.83M+448.4%
- 1995$7.45M-490.4%
- 1994−$1.91M-108.8%
- 1993$21.70M-24.1%
- 1992$28.60M-2300.0%
- 1991−$1.30M-262.5%
- 1990$800.00K-108.9%
- 1989−$9.00M-24.4%
- 1988−$11.90M-50.8%
- 1987−$24.20M-16.8%
- 1986−$29.10M-11.6%
- 1985−$32.90M—
Operating Income values are taken from Biogen's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Operating Income at Biogen (BIIB)
According to Biogen's latest reported financial statements, the company's current operating income (TTM) is $1.54B. Operating income is profit from core operations: revenue minus cost of goods sold and operating expenses (SG&A, R&D). It excludes interest, taxes, and non-operating items, so it isolates how profitable the business itself is before financing and tax decisions. Compare with EBITDA and net income.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
2025's annual operating income for Biogen (BIIB) came in at $1.88B – declined 24.6% year-over-year.
Biogen operating income compound annual growth for the 2020–2025 (5 years) window is -16.4%, with a net decline across the window.
Between 2019 and 2025, Biogen operating income plunged 73.3%, falling from $7.04B to $1.88B.
The highest annual operating income of $7.04B was reported in 2019. The lowest in the available history was −$869.67M in 2003.
Biogen Operating Income by Year
Biogen Operating Income 2025: $1.88B
Biogen posted operating income of $1.88B in 2025, declined 24.6% below 2024.
Biogen Operating Income 2024: $2.49B
In 2024, Biogen reported operating income of $2.49B, grew 18.7% from 2023.
Biogen Operating Income 2023: $2.10B
Biogen operating income in 2023 was $2.10B, declined 27.4% below 2022.
Biogen Operating Income 2022: $2.89B
2022's operating income for Biogen came in at $2.89B, edged up 3.5% from 2021.
Biogen Operating Income 2021: $2.79B
Biogen operating income in 2021 was $2.79B.
See more financial history for Biogen (BIIB).
Sector peers by Operating Income
Healthcare peers of Biogen (BIIB), ranked by their latest operating income
| $29.70B | |
| $25.60B | |
| $23.49B | |
| $20.09B | |
| $19.90B | |
| $18.96B | |
| $13.74B | |
| $10.68B |
- $29.70B
- $25.60B
- $23.49B
- $20.09B
- $19.90B
- $18.96B
- $13.74B
- $10.68B
Frequently asked questions
Biogen (BIIB) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation